Curis Inc at Needham Healthcare Conference (Virtual) - On-Demand Transcript
Good morning, and welcome to day 2 of the Annual Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Curis' CEO, Jim Dentzer. (Conference Instructions)
And with that, Jim, you have the stage.
Thank you, Gil, really appreciate it. Thank you for having us here today. I really appreciate the chance to talk about Curis. I have our corporate deck up. I'm not going to belabor every slide, but I'm going to hit through some of the high points. I think what we've got going on is really unique and compelling.
So first, what makes Curis different from other biotech companies is that we look to develop exclusively novel, first-in-class, cancer drugs. There are no me-too drugs at Curis. In addition, we take an approach where we are pursuing drugs that we believe have a significant potential in terms of unmet need. What does that mean? It means
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |